OTC
0.00USD
0.00 (0.00%)
We have scored 4 news catalysts on Aditxt, Inc. (ADTX) over the past 12 months. The biggest single-day move next to one of them came Jun 22, 2026, when ADTX closed +92.0%: “Why Sagtec Global Shares Are Trading Higher By Around 76%; Here Are 20 Stocks Moving Premarket”. Coverage across the window leans positive (average ticker sentiment +0.80). Most of the impact sits in forward growth expectations and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
399.2K
P/E
—
EPS
—
Beta
0.93
52W range
0.0001-1903.824
Day range
0.00–0.00
Open
0.00
Prev close
0.00
Volume
171.1K
Avg volume
296.9M
Dividend
0.00
IPO
2020-06-30
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Aditxt, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for ADTX: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Aditxt, Inc. is a biotechnology firm dedicated to advancing immune system health through innovative mapping and reprogramming techniques. The company's developments include AditxtScore, a platform designed to empower individuals by providing insights into their immune profiles for better management and informed awareness of immune system attacks or dysfunctions. Aditxt also pioneers Apoptotic DNA Immunotherapy, a nucleic acid-based solution that emulates the body's inherent mechanisms for developing self-tolerance to its own tissues. Additionally, Aditxt is actively researching and developing ADi products with diverse therapeutic applications, such as for organ transplant procedures (including skin grafting), various autoimmune conditions, and allergic reactions. The company holds licensing agreements with esteemed institutions like Loma Linda University and Leland Stanford Junior University. Established in 2017, this Richmond, Virginia-headquartered company was initially known as ADiTx Therapeutics, Inc. before rebranding to Aditxt, Inc. in July 2021.
